R.E.C.K vs Exparel in Robotic Nephrectomy

Recruiting now · Phase 3

Conditions studied: Renal Carcinoma, Nephrectomy / Methods, Pain Management

In brief

The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.

Key facts

Study ID: NCT07092566
Run by: Wake Forest University Health Sciences
People needed: 170
Starts: 2025-11-14
Expected to finish: 2027-10-01
Last updated by the study team: 2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Ability to understand and willingness to sign an IRB-approved informed consent
Age ≥ 18 years at the time of consent.
Planned robotic partial or radical nephrectomy

You may not qualify if…

Determined not to be a candidate to receive R.E.C.K or Exparel per the enrolling investigator
Known pregnancy
Chronic opioid use within 30 days (as per patient report) prior to randomization (defined as ≥ 30 MME/day)
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
Known allergy to R.E.C.K. and/or Exparel

Where it is running

Levine Cancer — Charlotte, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.